A. Kivitz

768 citations

32 papers · 522 indexed · h-index 9

Co-authors: Christophe Schmitt Susan Grange Bernd Kuhn R. W. Moskowitz E. Woods Roy Fleischmann Christopher J. Swearingen John Hood
Topics: Rheumatoid Arthritis Research and Therapies (19 papers)Spondyloarthritis Studies and Treatments (10 papers)Chronic Lymphocytic Leukemia Research (5 papers)
Cited by: Rheumatology Pharmacology
Journals: Annals of the Rheumatic Diseases Clinical Pharmacology & Therapeutics Bone
Partner nations: United States United Kingdom Netherlands

In The Last Decade

A. Kivitz

31 papers receiving 504 citations

Peers

Countries citing papers authored by A. Kivitz

Since Specialization

Citations

This map shows the geographic impact of A. Kivitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kivitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kivitz more than expected).

Fields of papers citing papers by A. Kivitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kivitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kivitz. The network helps show where A. Kivitz may publish in the future.

Co-authorship network of co-authors of A. Kivitz

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kivitz. A scholar is included among the top collaborators of A. Kivitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kivitz. A. Kivitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS 2023 ·Annals of the Rheumatic Diseases ·Jay Tuttle,Edit Drescher,Jesus Abraham Simón Campos,Paul Emery,Maria Greenwald,A. Kivitz,(unknown),Pia P. Yachi,(unknown),Ajay Nirula	1
2	OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY 2020 ·Annals of the Rheumatic Diseases ·Jürgen Braun,Ricardo Blanco,Eva Dokoupilová,Lianne S. Gensler,A. Kivitz,Stephen Hall,Hideto Kameda,Denis Poddubnyy,M. Van de Sande,D. van der Heijde,Anna Wiksten,Brian Porter,H. Richards,Sibylle Haemmerle,Atul Deodhar	5
3	Triamcinolone acetonide extended-release injectable suspension (TA-ER) is associated with reduced blood glucose elevation vs. standard triamcinolone in type 2 diabetes mellitus patients with knee osteoarthritis: a randomized, blinded, parallel-group study 2018 ·Osteoarthritis and Cartilage ·Philip G. Conaghan,(unknown),(unknown),George Habib,(unknown),Robert Manning,A. Kivitz,(unknown),Joelle Lufkin,James R. Johnson,Scott D. Kelley	3
4	SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study 2018 ·Annals of the Rheumatic Diseases ·Peter Nash,Laura C. Coates,A. Kivitz,Philip J. Mease,Dafna D. Gladman,(unknown),Dona Fleishaker,C. Wang,Elizabeth M. Kudlacz,Sujatha Menon,Lara Fallon,Thijs Hendrikx,Keith S. Kanik	9
5	OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial 2018 ·Annals of the Rheumatic Diseases ·Philip J. Mease,H. Kellner,Akimichi Morita,A. Kivitz,Kim Papp,Stella Aslanyan,Bret Berner,(unknown),Ann Eldred,Frank Behrens	42
6	Fasinumab in the treatment of hip and knee osteoarthritic pain: efficacy and safety in a 36-week randomized, double-blind placebo-controlled clinical trial 2017 ·Osteoarthritis and Cartilage ·Jennifer Maloney,A. Kivitz,Thomas J. Schnitzer,Paula Dakin,(unknown),Haitao Gao,C. Stehman-Breen,Gregory P. Geba	3
7	A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study 2017 ·Osteoarthritis and Cartilage ·Yusuf Yazıcı,Timothy E. McAlindon,Roy Fleischmann,Allan Gibofsky,N.E. Lane,A. Kivitz,Nebojša Skrepnik,(unknown),Christopher J. Swearingen,A. DiFrancesco,J. Tambiah,John Hood,Marc C. Hochberg	108
8	THU0422 Apremilast Monotherapy as The First Systemic Treatment in DMARD-Naïve Patients with Active Psoriatic Arthritis: 3-Year Treatment Results 2016 ·Annals of the Rheumatic Diseases ·(unknown),C. J. Edwards,A. Kivitz,Paul Bird,(unknown),K. Shah,Lichen Teng,Jacob Aelion	1
9	SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2) 2016 ·Annals of the Rheumatic Diseases ·Helena Marzo‐Ortega,Clarence W. Legerton,J. Sieper,A. Kivitz,Ricardo Blanco,Maxime C. Cohen,(unknown),Aimee Readie,Brian Porter,H. Richards	1
10	Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis 2014 ·The Journal of Rheumatology ·Walter P. Maksymowych,R. Landewé,Martín Rudwaleit,D. van der Heijde,Maxime Dougados,Philip J. Mease,John D. Reveille,Jessica A. Walsh,A. Kivitz,(unknown),Atul Deodhar,C. Stach,Bengt Hoepken,Pritam Singh,J. Sieper	3
11	Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study 2014 ·Value in Health ·Joachim Sieper,A. Kivitz,Astrid van Tubergen,Atul Deodhar,(unknown),T. Nurminen,Robert Landewé	4
12	THU0109 Lack of Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study 2014 ·Annals of the Rheumatic Diseases ·A. Kivitz,Paulo Maciag,Parul Gulati,Shuyan Du,Seán Connolly,Paul Davies,(unknown),(unknown),Helen G. Haggerty,Marco Londei	4
13	SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial 2014 ·Annals of the Rheumatic Diseases ·Ade Adebajo,(unknown),Christopher J Edwards,A. Kivitz,Paul Bird,K. Shah,(unknown),(unknown),Jacob Aelion	2
14	Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study 2013 ·Value in Health ·Joachim Sieper,A. Kivitz,Astrid van Tubergen,Atul Deodhar,G. Coteur,Franz Woltering,Robert Landewé	7
15	THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial 2013 ·Annals of the Rheumatic Diseases ·Gerd R Burmester,A. Kivitz,Ronald van Vollenhoven,S. Florentinus,(unknown),H. Küpper,Maxime Dougados,Roy Fleischmann	2
16	Effects of multiple doses of the sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass 2012 ·Bone ·(unknown),Mark Allison,A. Kivitz,María J. Gutiérrez,Brian Stouch,(unknown),Graham Jang	1
17	Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis 2011 ·Clinical Pharmacology & Therapeutics ·Christophe Schmitt,Bernd Kuhn,(unknown),A. Kivitz,Susan Grange	189
18	Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS) 2008 ·Oxford University Research Archive (ORA) (University of Oxford) ·Désirée van der Heijde,Ben A. C. Dijkmans,(unknown),A. Kivitz,Kurt De Vlam,P Wordsworth,Shaila Ballal,H. Küpper,(unknown),J. Sieper,(unknown)	2
19	Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients 2008 ·Pediatric Rheumatology ·Nicolino Ruperto,D. Lovell,(unknown),Pierre Quartier,José Chávez,Christian Huemer,A. Kivitz,Francisco J. Blanco,Ivan Foeldvari,Michaël Hofer,Leonard H. Sigal,A. Jay Block,A. Covucci,Alberto Martini,(unknown)	1
20	Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. 2006 ·Oxford University Research Archive (ORA) (University of Oxford) ·Désirée van der Heijde,A. Kivitz,Michael Schiff,J. Sieper,(unknown),Jürgen Braun,Maxime Dougados,P Wordsworth,(unknown),H. Küpper,John W. Davis	4

About A. Kivitz

A. Kivitz is a scholar working on Rheumatology, Hematology and Immunology, having authored 32 papers that have together received 522 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (19 papers), Spondyloarthritis Studies and Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Rheumatology (259 citations), Pharmacology (95 citations) and Pharmacology (147 citations). A. Kivitz has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Christophe Schmitt, Susan Grange, Bernd Kuhn, R. W. Moskowitz, E. Woods, Roy Fleischmann, Christopher J. Swearingen, John Hood, Allan Gibofsky and Marc C. Hochberg. Their work appears in journals such as Annals of the Rheumatic Diseases, Clinical Pharmacology & Therapeutics and Bone.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact